AlphAIAlphAI — Financial news for AI agents
cnbc.comOCT 292 min read$MRK

Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength

Merck reported Q3 earnings of $2.49 per share (adjusted) and $18.09B revenue, exceeding estimates. The company raised its adjusted profit outlook to $2.77-$2.82 per share, citing strong sales of Keytruda and its new form, Keytruda Qlex, which brought in $8.6B and $830M respectively. Merck also narrowed its 2026 revenue guidance to $66.8B-$67.3B. Other products like Winrevair and Gardasil showed significant growth.

Original reporting
cnbc.com
Published Oct 29, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strength — source image
Source · cnbc.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to boost MRK's stock price, while the one‑time charge tempers the upside.

02

Market read

Merck's earnings beat and upgraded outlook provide a fresh catalyst for the stock and may influence the broader pharma sector.

03

What to watch

Potential competitive pressure from biosimilars and the cost of scaling the new injectable form may limit long‑term growth.

Relevance 9/10Novelty 9/10Timing: after-hours

Background

Merck's Q3 results highlight a rebound in sales from its flagship immunotherapy Keytruda, including the newer injectable Qlex version.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck reported Q3 earnings beating estimates and raised its adjusted earnings outlook to $2.77‑$2.82 per share, adding a $400 M one‑time charge.

Expected impact

potential upside as investors price in higher earnings guidance and robust immunotherapy sales

Evidence & confidence

The earnings beat and upgraded profit outlook are primary, material news for a large‑cap pharma, likely to drive buying pressure in the near term.

Market effects

Sector

Biotech and oncology segments may see broader rally on Keytruda momentum.

Regional

U.S. healthcare stocks could gain as Merck's guidance lifts sector sentiment.

Global

International investors tracking pharma earnings may adjust exposure to large‑cap drug makers.

Counterpoint

What could challenge this read

The $400 M charge and upcoming patent expirations could temper upside, prompting a short‑term pullback.

Key entities

  • company
    Merck & Co.

    Global pharmaceutical company reporting Q3 earnings.

  • product
    Keytruda

    Merck's immunotherapy drug, now offered in an injectable form.

Read at source← All news

StoryMerck reports Q3 2026 earnings beat and raises 2026 revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 29
$LLYMed

Drugmakers Shrug Off Trump Pricing Pressure With Record Revenue

Three major US drugmakers—Eli Lilly, Merck, and Bristol Myers Squibb—reported record quarterly revenue and raised annual forecasts, citing strong demand for treatments. Despite Trump's pricing pressure, shares rose significantly. The companies expect volume growth to offset any price reductions. The White House highlighted savings programs as accomplishments.

finance.yahoo.com2 min
OCT 29
$MRKHighAI 9/10

Merck Q3 2026 earnings top estimates as profit forecast rises

Merck reported Q3 2026 sales of $18.1B, up 5%, and adjusted earnings of $2.49/share, beating estimates. The company raised its full-year sales forecast to $66.8B-$67.3B. Keytruda (Qlex) sales were $830M, the highest since launch. Winrevair sales rose 93% to $694M. Animal health sales increased 4% to $1.7B.

qz.com2 min